DDMAC raps sponsored links for omission of risk info

Share this article:
DDMAC raps sponsored links for omission of risk info
DDMAC raps sponsored links for omission of risk info
The FDA's Division of Drug Marketing, Advertising and Communications slapped 14 drug companies with untitled letters for sponsored links on Google deemed violative because they omitted risk information.

DDMAC sent the letters, dated March 26, to Biogen Idec, Sanofi-Aventis, GlaxoSmithKline, Forest Laboratories, Cephalon, Bayer, Johnson & Johnson, Pfizer, Novartis, Genentech, Boehringer Ingelheim, Merck, Lilly and Hoffman-LaRoche, requesting that they pull the sponsored links in question.

Sponsored links appear as a highlighted bar atop Google searches, with room for 95 characters, including headline -- little more than a short sentence describing the product advertised. A sponsored link for Lilly's Cymbalta that the agency found violative featured a link, the URL for the product site and the line: “Learn about an SNRI for depression called Cymbalta (duloxetine HCI).”

In its letter to Lilly, the agency said “Promotional materials, other than reminder pieces, which include the name of the drug product but do not include indications or other representations or suggestions relative to the drug product, are required to disclose risk and other information about the drug.” The letter noted that the sponsored link did contain a link to the product site but said “this is insufficient to mitigate the misleading omission of risk information from these promotional materials.” The letter also noted that Cymbalta carries a boxed warning.

An agency spokesperson said in an email to MM&M that companies are subject to rules regarding disclosure of risk and other information “even if they choose to do so using a promotional vehicle that has space limitations,” and suggested that unbranded pieces or reminder promotions might serve as alternatives for space-restricted formats. Reminder promotions can feature the name of a drug but not indications, dosage recommendations or other representations of safety or effectiveness, but are not allowed for drugs that, like Cymbalta, carry boxed warnings. “Note that we have observed many compliant promotional pieces of this type during our monitoring of prescription promotion on the Internet,” said the spokesperson.

In addition to the lack of risk information, the letters also called out some sponsored links for failing to include the generic or molecule name as well as the brand name of the drug and for incomplete or misleading indications. The target companies have until April 9 to respond to the agency in writing.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...